Microglial activation-sensitive gadolinium complex as a potential MRI contrast agent for Alzheimer’s disease diagnosis

Abstract

Numerous studies have developed gadolinium (Gd)-based contrast agents (GBCAs) for in-vivo magnetic resonance imaging (MRI) with the aim of diagnosing Alzheimer’s disease (AD). Nevertheless, GBCAs that are capable of identifying microglial activation, a critical early indicator of AD pathology, for in-vivo diagnosis remain scarce. In response to this, we synthesized a novel GBCA, Gd-DO3A-Va, designed specifically to detect microglial activation using MRI. This innovative GBCA, which was conjugated with vanillic acid, demonstrated a high selectivity for microglial activation by targeting Toll-like receptor 4 (TLR4). The use of Gd-DO3A-Va in in-vivo imaging successfully highlighted microglial activation in a transgenic AD mouse model. In particular, the use of Gd-DO3A-Va for contrast-enhanced T1-weighted MRI enabled the detection of microglial activation within the hippocampus and cortex, regions notably affected by AD. The observed enhancements in the MR contrast correlated well with immunohistological evidence of microglial activation. Consequently, Gd-DO3A-Va represents a highly promising GBCA for the identification of microglial activation, providing a novel pathway for the molecular diagnosis of AD.